Ganciclovir

Generic Name: Ganciclovir

Brand Names: Cytovene, Zirgan

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₅O_₄

CAS Number: 82410-32-0

Unique Ingredient Identifier: P9G3CKZ4P5

Background: An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.

Indication: For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients.

Associated Conditions: CMV colitis, Cytomegalovirus (CMV) Infections, Cytomegalovirus Retinitis, Cytomegalovirus gastroesophagitis, Varicella-zoster Progressive outer retinal necrosis, Acute Herpetic keratitis, Cytomegalovirus neurological disease, Varicella-zoster virus acute retinal necrosis

Associated Therapies: -

Clinical Trials

Gene Therapy in Treating Patients With Primary Brain Tumors

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-07-29

Last Posted Date: 2019-03-13

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Registration Number: NCT00002824

Locations: 🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States

Vaccine Therapy and Ganciclovir in Treating Patients With Mesothelioma

Phase 1

Conditions: Malignant Mesothelioma

First Posted Date: 2004-04-26

Last Posted Date: 2013-09-20

Lead Sponsor: Louisiana State University Health Sciences Center in New Orleans

Registration Number: NCT00006216

Locations: 🇺🇸
Louisiana State University School of Medicine, New Orleans, Louisiana, United States

Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma

Phase 1

Completed

Conditions: Neuroblastoma

First Posted Date: 2003-12-31

Last Posted Date: 2010-09-21

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00006480

Locations: 🇺🇸
Cancer Center and Beckman Research Institute, City of Hope, Duarte, California, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Phase 2

Conditions: Fallopian Tube Cancer
Primary Peritoneal Cavity Cancer
Ovarian Cancer

First Posted Date: 2003-05-05

Last Posted Date: 2013-11-06

Lead Sponsor: John Stoddard Cancer Center at Iowa Methodist Medical Center

Registration Number: NCT00005025

Locations: 🇺🇸
Human Gene Therapy Research Institute, Des Moines, Iowa, United States

Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus

Phase 1

Completed

Conditions: Leukemia
Lymphoma
Precancerous Condition
Small Intestine Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-26

Lead Sponsor: Boston Medical Center

Registration Number: NCT00006340

Locations: 🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany
🇺🇸
Cancer Research Center at Boston Medical Center, Boston, Massachusetts, United States
🇮🇹
Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy

and more 3 locations

Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2016-02-03

Lead Sponsor: AIDS Malignancy Consortium

Registration Number: NCT00006264

Locations: 🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
🇺🇸
Sylvester Cancer Center, University of Miami, Miami, Florida, United States

Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation

Phase 3

Completed

Conditions: Infection

First Posted Date: 2003-01-27

Last Posted Date: 2010-05-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 184

Registration Number: NCT00016068

Locations: 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
University of Florida Shands Cancer Center, Gainesville, Florida, United States

and more 4 locations

Valganciclovir in Congenital CMV Infants

Phase 1

Completed

Conditions: Cytomegalovirus Infections

Interventions: Drug: Valganciclovir
Drug: Ganciclovir

First Posted Date: 2002-03-07

Last Posted Date: 2011-02-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT00031434

Locations: 🇺🇸
University of Louisville, Louisville, Kentucky, United States
🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States
🇺🇸
Cook Children's Medical Center, Fort Worth, Texas, United States

and more 18 locations

A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS

Not Applicable

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 100

Registration Number: NCT00002034

Locations: 🇺🇸
Dr Alfred F Burnside Jr, Columbia, South Carolina, United States
🇺🇸
SUNY / Health Sciences Ctr at Stony Brook, Stony Brook, New York, United States
🇨🇦
Southern Alberta HIV Clinic / Foothills Hosp, Calgary, Alberta, Canada

and more 6 locations

A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir Therapy

Not Applicable

Completed

Conditions: Cytomegalovirus Retinitis
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 225

Registration Number: NCT00002247

Locations: 🇺🇸
Mount Zion Med Ctr, San Francisco, California, United States
🇺🇸
Dr Dorothy Friedberg, New York, New York, United States
🇺🇸
Georgetown Univ Med Ctr, Washington, District of Columbia, United States

and more 17 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy